Kolon TissueGene and Kolon Life Science hit daily limit down on news of no significant efficacy in US trial
Reliability 66 · high1 h ago
- Right1
- Agency1
2 sources2 independent voices
no rewrites detected — all voices distinct
Summary
On the 21st, early in the session, Kolon Group went straight to the lowest end of the daily limit down.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
On the 21st, early in the session, Kolon Group went straight to the lowest end of the daily limit down.
according to Chosun Ilbo
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Right1
Agency1
